NT Mobile Menu

Search form


Andrew N. Wilner, MD

Andrew N. Wilner, MD

Dr. Andrew Wilner graduated from Yale University and Brown University SchoolAndrew Wilner, MD of Medicine. He is board certified in internal medicine and neurology. He completed a fellowship in electroencephalography at the Montreal Neurological Institute, Montreal, Canada. He was medical director of the Carolinas Epilepsy Center, Charlotte, NC, and then Clinical Associate Professor of Neurology at Brown University School of Medicine, Providence, RI. Currently, he is a practicing locum tenens neurologist and Assistant Professor of Neurology at the Mayo Clinic.

Dr. Wilner has been a medical advisor for Accordant Health Services Epilepsy Disease Management Program, Greensboro, NC, for more than 15 years. Dr. Wilner and Accordant colleagues have published papers in Epilepsy and Behavior detailing the excess cost burden of epilepsy compared to controls and highlighted the problem of comorbidities (Wilner et al. 2012, 2014, 2016).

Dr. Wilner has worked for many years as medical journalist with more than 1,000 publications. He is also a radio host for ReachMD.com

He received the American Academy of Neurology's Creative Expression of Human Values Award (2001), the American Academy of Neurology's Journalism Fellowship for Excellence in Medical/Health Reporting (2008), and is the author of two books on epilepsy; Epilepsy: 199 Answers, 3rd Edition, and Epilepsy in Clinical Practice. He was a Section Editor for the 3-volume Atlas of Epilepsies (Springer, 2010). His latest book, Bullets and Brains, a collection of over 100 essays on neurology, was published in 2013.

Dr. Wilner volunteers as the medical director of Lingkod Timog, a nonprofit medical mission organization that delivers health care to rural areas of the Philippines. For more information, see www.drwilner.org and bulletsandbrains.net.

Posts by Author

An expert discusses the latest guidelines to reduce brain injury in adults who are comatose after cardiac resuscitation.

Key details about an option for the treatment of drug-resistant epilepsy in patients who are not surgical candidates.

Here’s a case in point about PML, and key points about this viral disease of the CNS.

What do the new AAN guidelines on SUDEP offer? Here’s a quick overview of the key facts.

Early treatment of clinically isolated syndrome (CIS) with subcutaneous interferon beta 1b (IFN-b-1b; Betaseron) may reduce disability at 3 years, according to the latest news from the Betaferon/Betaseron in Newly Emerging MS For Initial Treatment (BENEFIT) study. The data were presented by Mark Freedman, MD, director of the Multiple Sclerosis Research Unit at the University of Ottawa, in Ontario, at the recent Annual Meeting of the American Academy of Neurology (AAN), held April 28 to May 5 in Boston.

HHD, which affects only a small percentage (4%) of patients with PD, is characterized by adverse psychomotor effects related to dopamine replacement therapy.

epilepsy, seizures

By clicking Accept, you agree to become a member of the UBM Medica Community.